314 related articles for article (PubMed ID: 31434794)
1. Plasmalogen loss caused by remodeling deficiency in mitochondria.
Kimura T; Kimura AK; Ren M; Monteiro V; Xu Y; Berno B; Schlame M; Epand RM
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31434794
[TBL] [Abstract][Full Text] [Related]
2. Interplay between cardiolipin and plasmalogens in Barth syndrome.
Bozelli JC; Epand RM
J Inherit Metab Dis; 2022 Jan; 45(1):99-110. PubMed ID: 34655242
[TBL] [Abstract][Full Text] [Related]
3. Promotion of plasmalogen biosynthesis reverse lipid changes in a Barth Syndrome cell model.
Bozelli JC; Lu D; Atilla-Gokcumen GE; Epand RM
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jun; 1865(6):158677. PubMed ID: 32126285
[TBL] [Abstract][Full Text] [Related]
4. Substantial Decrease in Plasmalogen in the Heart Associated with Tafazzin Deficiency.
Kimura T; Kimura AK; Ren M; Berno B; Xu Y; Schlame M; Epand RM
Biochemistry; 2018 Apr; 57(14):2162-2175. PubMed ID: 29557170
[TBL] [Abstract][Full Text] [Related]
5. Aberrant cardiolipin metabolism is associated with cognitive deficiency and hippocampal alteration in tafazzin knockdown mice.
Cole LK; Kim JH; Amoscato AA; Tyurina YY; Bay R H; Karimi B; Siddiqui TJ; Kagan VE; Hatch GM; Kauppinen TM
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3353-3367. PubMed ID: 30055293
[TBL] [Abstract][Full Text] [Related]
6. Cardiac metabolic pathways affected in the mouse model of barth syndrome.
Huang Y; Powers C; Madala SK; Greis KD; Haffey WD; Towbin JA; Purevjav E; Javadov S; Strauss AW; Khuchua Z
PLoS One; 2015; 10(6):e0128561. PubMed ID: 26030409
[TBL] [Abstract][Full Text] [Related]
7. Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.
Le CH; Benage LG; Specht KS; Li Puma LC; Mulligan CM; Heuberger AL; Prenni JE; Claypool SM; Chatfield KC; Sparagna GC; Chicco AJ
J Biol Chem; 2020 Aug; 295(35):12485-12497. PubMed ID: 32665401
[TBL] [Abstract][Full Text] [Related]
8. Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.
Zhu S; Chen Z; Zhu M; Shen Y; Leon LJ; Chi L; Spinozzi S; Tan C; Gu Y; Nguyen A; Zhou Y; Feng W; Vaz FM; Wang X; Gustafsson AB; Evans SM; Kunfu O; Fang X
Circ Heart Fail; 2021 Jun; 14(6):e008289. PubMed ID: 34129362
[TBL] [Abstract][Full Text] [Related]
9. Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome.
Zhang J; Liu X; Nie J; Shi Y
Autophagy; 2022 Sep; 18(9):2134-2149. PubMed ID: 34985382
[TBL] [Abstract][Full Text] [Related]
10. Barth syndrome cells display widespread remodeling of mitochondrial complexes without affecting metabolic flux distribution.
Chatzispyrou IA; Guerrero-Castillo S; Held NM; Ruiter JPN; Denis SW; IJlst L; Wanders RJ; van Weeghel M; Ferdinandusse S; Vaz FM; Brandt U; Houtkooper RH
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3650-3658. PubMed ID: 30251684
[TBL] [Abstract][Full Text] [Related]
11. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy.
Chatfield KC; Sparagna GC; Specht KS; Whitcomb LA; Omar AK; Miyamoto SD; Wolfe LM; Chicco AJ
J Inherit Metab Dis; 2022 Jan; 45(1):111-124. PubMed ID: 34821394
[TBL] [Abstract][Full Text] [Related]
12. Loss of tafazzin results in decreased myoblast differentiation in C2C12 cells: A myoblast model of Barth syndrome and cardiolipin deficiency.
Lou W; Reynolds CA; Li Y; Liu J; Hüttemann M; Schlame M; Stevenson D; Strathdee D; Greenberg ML
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Aug; 1863(8):857-865. PubMed ID: 29694924
[TBL] [Abstract][Full Text] [Related]
13. The Role of Cardiolipin in Cardiovascular Health.
Shen Z; Ye C; McCain K; Greenberg ML
Biomed Res Int; 2015; 2015():891707. PubMed ID: 26301254
[TBL] [Abstract][Full Text] [Related]
14. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.
Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA
J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285
[TBL] [Abstract][Full Text] [Related]
15. Experimental models of Barth syndrome.
Pu WT
J Inherit Metab Dis; 2022 Jan; 45(1):72-81. PubMed ID: 34370877
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.
Russo S; De Rasmo D; Signorile A; Corcelli A; Lobasso S
Sci Rep; 2022 Nov; 12(1):19847. PubMed ID: 36400945
[TBL] [Abstract][Full Text] [Related]
17. Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy.
Ikon N; Ryan RO
Lipids; 2017 Feb; 52(2):99-108. PubMed ID: 28070695
[TBL] [Abstract][Full Text] [Related]
18. Barth Syndrome Cardiomyopathy: An Update.
Pang J; Bao Y; Mitchell-Silbaugh K; Veevers J; Fang X
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456462
[TBL] [Abstract][Full Text] [Related]
19. N-oleoylethanolamide treatment of lymphoblasts deficient in Tafazzin improves cell growth and mitochondrial morphology and dynamics.
Chan JZ; Fernandes MF; Steckel KE; Bradley RM; Hashemi A; Groh MR; Sciaini G; Stark KD; Duncan RE
Sci Rep; 2022 Jun; 12(1):9466. PubMed ID: 35676289
[TBL] [Abstract][Full Text] [Related]
20. Cardiolipin deficiency elevates susceptibility to a lipotoxic hypertrophic cardiomyopathy.
Cole LK; Mejia EM; Sparagna GC; Vandel M; Xiang B; Han X; Dedousis N; Kaufman BA; Dolinsky VW; Hatch GM
J Mol Cell Cardiol; 2020 Jul; 144():24-34. PubMed ID: 32418915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]